+1 (304) 470-2225

Bristols’ DLBCL CAR-T Therapy -Lisocabtagene Maraleucel (JCAR017) Future Strategy & Latest Events

Liso-cel Strategy

Lisocabtagene maraleucel, also known as liso-cel and JCAR017 is a 4-1BB-based second generation CAR-T therapy, that contains a distinct IgG4-based hinge. The therapy is a key pipeline asset which Bristol-Myers picked up through its takeover […]

Read More

Gene Research collaboration of Cabaletta Bio’s CABA Platform (CAART cell therapy) & Artisan Bio’s STARS Platform (Genome engineering)


Artisan bio entered into a gene editing research agreement with Cabaletta, which allows it to integrate Artisan’s advanced gene editing and engineering technology into Cabeletta’s next-generation CAAR T products as the company continues to expand […]

Read More

Intellia’s CRISPER/Cas9 and Teneobio’s UniAb technology providing a new dimension to cell therapy

Tenebio Strategy 2021

A clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), Teneobio and a leading genome editing company focused on developing proprietary curative therapeutics using the CRISPR/Cas9 system i.e Intellia therapeutics […]

Read More

Get In Touch

Let's keep the conversation going